AHFS DI® Essentials: What's New in May 2009

AHFS DI® Essentials™

©2009 by the American Society of Health-System Pharmacists, Inc.

Authors/Editors: Gerald K. McEvoy, Pharm.D.

May 2009

New Monographs:

Opium: Opiate agonist and antiperistaltic agent; naturally occurring phenanthrene derivative; contains several alkaloids, including anhydrous morphine, codeine, and papaverine.

Revised Monographs:

Amantadine: Antiviral; antiparkinsonian agent; adamantane derivative.

Botulinum Toxin Type A: Neurotoxin produced by Clostridium botulinum; 7 structurally similar but antigenically and serologically distinct serotypes (A, B, C, D, E, F, and G) exist.

Botulinum Toxin Type B: Neurotoxin produced by Clostridium botulinum; 7 structurally similar but antigenically and serologically distinct botulinum toxin serotypes (A, B, C, D, E, F, and G) exist.

Ceftriaxone: Antibacterial; b-lactam antibiotic; third generation cephalosporin.

Clindamycin (Topical): Antibacterial; broad-spectrum antibiotic derived from lincomycin.

Oseltamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.

Paricalcitol: A synthetic vitamin D analog.

Rimantadine: Antiviral; adamantane derivative.

Rivastigmine: A centrally active, reversible cholinesterase inhibitor.

Zanamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.

The Medical Letter® On Drugs and Therapeutics-What's New in May 2009

The Medical Letter® On Drugs and Therapeutics

©2009-1995 The Medical Letter, Inc.

Authors/Editors: Mark Arbramwicz, MD et. al.

The Medical Letter on Drugs and Therapeutics is an independent, nonprofit publication that offers unbiased critical evaluations of drugs for physicians and other members of the health professions. This resource evaluates virtually all new drugs and also reviews older drugs when important new information becomes available on their usefulness or adverse effects. It is only available to single users online and covers the period from 1995-2008.* This title updates: Monthly * Available as a single user subscription only.

2009 - VOLUME 51 (ISSUES 1303-1311)

May 4, 2009 (Issue 1311)

Fenofibric Acid (Trilipix) [51:1311]

Fesoterodine (Toviaz) for Overactive Bladder [51:1311]

Drugs for MRSA with Reduced Susceptibility to Vancomycin [51:1311]

Tables

Table 1311-1. Fenofibrate Products Table

1311-2. Results of Clinical Trials

Table 1311-3. Drugs for Overactive Bladder

ACP PIER and AHFS DI Essentials: What's New in May 2009

ACP PIER & AHFS DI® Essentials™

 ©2009 ACP PIER: American College of Physicians ©2008 AHFS DI® Essentials™ Authors/Editors: ACP PIER: American College of Physicians (ACP) © 2008 by the American College of Physicians

New Monographs:

Opium: Opiate agonist and antiperistaltic agent; naturally occurring phenanthrene derivative; contains several alkaloids, including anhydrous morphine, codeine, and papaverine.

Revised Monographs:

Amantadine: Antiviral; antiparkinsonian agent; adamantane derivative.

Botulinum Toxin Type A: Neurotoxin produced by Clostridium botulinum; 7 structurally similar but antigenically and serologically distinct serotypes (A, B, C, D, E, F, and G) exist.

Botulinum Toxin Type B: Neurotoxin produced by Clostridium botulinum; 7 structurally similar but antigenically and serologically distinct botulinum toxin serotypes (A, B, C, D, E, F, and G) exist.

Ceftriaxone: Antibacterial; b-lactam antibiotic; third generation cephalosporin.

Clindamycin (Topical): Antibacterial; broad-spectrum antibiotic derived from lincomycin.

Oseltamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.

Paricalcitol: A synthetic vitamin D analog.

Rimantadine: Antiviral; adamantane derivative.

Rivastigmine: A centrally active, reversible cholinesterase inhibitor.

Zanamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.

Product Update: CD&T in Gastro Updated

Product Update: CD&T in Gastro Updated

Current Diagnosis & Treatment in Gastroenterology (2003) replaced with Current Diagnosis and Treatment in Gastroenterology, Hepatology and Endoscopy (2009)

STAT!Ref subscriptions that currently includes Current Diagnosis & Treatment in Gastroenterolgy, 2nd Edition (2003) will be automatically replaced with Current Diagnosis and Treatment in Gastroenterology, Hepatology and Endoscopy, 3rd Edition (2009) at no charge in your subscription. This seamless update will not change any of your direct links. You may, however, want to update the title name in any lists that you may have on your Web sites, newsletters, curricula, etc. Please contact your STAT!Ref representative if you have any questions or concerns.

About Current Diagnosis and Treatment in Gastroenterology, Hepatology and Endoscopy 3rd Edition (2009): Current Diagnosis and Treatment in Gastroenterology, Hepatology and Endoscopy provides complete coverage of diagnosing and treating digestive tract and liver disorders. Edited by the world-renowned team at Brigham and Women's Hospital of Harvard University, this new addition to the popular CURRENT series provides you with all you need to know for diagnosing and treating digestive tract and liver disorders.

Features:

• High-yield coverage of the entire spectrum of gastroenterology and hepatology, from stomach and esophageal to pancreatic and liver disorders
• Complete review of advances in diagnostic and therapeutic endoscopy
• “Essentials of Diagnosis” bulleted lists deliver instant guidance on identifying both common and rare digestive disorders
• Over 90 full-color endoscopic and other images of GI disorders
• Over 50 radiographic images clarify the use of the many currently available imaging techniques
• Key information from related fields, including GI surgery, and subspecialities such as liver transplantation, bariatric surgery, inflammatory bowel disease and motility disorder
• Doody’s Core Title (DCT) and Essential Purchase Title (EPT)

Editor:

Norton J. Greenberger, MD

Clinical Professor of Medicine, Harvard Medical

School Senior Physician, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA

Associate Editors:

Richard S. Blumberg, MD

Professor of Medicine, Harvard Medical School

Chief, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA

Robert Burakoff, MD, MPH

Associate Professor of Medicine, Harvard Medical School

Clinical Chief of Gastroenterology, Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA

ACP Journal Club: What's New in May 2009

ACP Journal Club
by Brian Haynes, MD, PhD
American College of Physicians (2009)

ACP Journal Club, published by the American College of Physicians, is the quintessential evidence-based journal and is often positioned near the top of the EBM pyramid. Published monthly, it selects articles from the biomedical literature that report original studies and systematic reviews that warrant immediate attention by physicians attempting to keep pace with important advances in internal medicine. These articles are then summarized in value-added abstracts and commented on by clinical experts.

May 2009 - Volume 150, Number 5

Therapeutics

Review: Pneumococcal vaccination is not effective for preventing pneumonia, bacteremia, bronchitis, or mortality Selective decontamination of the digestive tract and selective oropharyngeal decontamination reduced mortality in the ICU

Review: Evidence is insufficient to evaluate effectiveness of antiviral therapies for chronic hepatitis B Fractional flow reserve-guided PCI reduced major adverse cardiac outcomes compared with angiography-guided PCI in multivessel CAD Benazepril plus amlodipine reduced cardiovascular risk more than benazepril plus hydrochlorothiazide

Quality Improvement

Intensive primary care treatment reduced cardiovascular risk factors at 1 year in screen-detected type 2 diabetes

Therapeutics

Irbesartan did not reduce all-cause death or CV hospitalization in heart failure and preserved ejection fraction Review: Adding dexamethasone to standard therapy reduces short-term relapse for acute migraine in the emergency department

Diagnosis

Review: Computed tomography angiography is highly accurate for diagnosing significant stenosis in peripheral arterial disease

Quality Improvement

Implementation of an evidence-based feeding guideline did not reduce mortality in intensive care units

Clinical Prediction Guide

The Glasgow-Blatchford Bleeding Score identified patients with upper GI bleeding who could be managed as outpatients Absolute CVD risk, stratified by risk score, was 20% higher in primary care patients with CVD than in those without CVD

Detailed Drug Information for the Consumer™ - What's New in April 2009

Detailed Drug Information for the Consumer™

 ©2009 Thomson Healthcare, Inc.

Authors/Editors: Thomson Healthcare, Inc.

New Monographs:

AMOXICILLIN AND CLAVULANATE (Oral route)

AMPICILLIN AND SULBACTAM (Injection route)

ARTEMETHER AND LUMEFANTRINE (Oral route)

BENZOCAINE (Oral route, Oromucosal route)

BENZOCAINE (Topical application route)

DIBUCAINE (Topical application route)

DIVALPROEX SODIUM (Oral route)

EVEROLIMUS (Oral route)

HALOPERIDOL (Intramuscular route)

ISOSORBIDE DINITRATE (Oral route, Sublingual route)

ISOSORBIDE MONONITRATE (Oral route)

JAPANESE ENCEPHALITIS VIRUS VACCINE, INACTIVATED ADSORBED (Intramuscular route)

LIDOCAINE (Topical application route)

LIDOCAINE AND HYDROCORTISONE (Topical application route)

LIDOCAINE AND TETRACAINE (Topical application route)

NITROGLYCERIN (Intravenous route)

NITROGLYCERIN (Oral route, Sublingual route)

NITROGLYCERIN (Transdermal route)

PHENOL (Oromucosal route)

PHENYTOIN (Oral route)

PIPERACILLIN AND TAZOBACTAM (Intravenous route)

SCOPOLAMINE (Transdermal route)

TETRACAINE (Topical application route)

TICARCILLIN AND CLAVULANATE (Intravenous route)

VALPROIC ACID (Oral route)

DrugPoints® System - What's New in April 2009

DrugPoints® System

©2009 Thomson Healthcare, Inc.

Authors/Editors: Thomson Healthcare, Inc.

New Monographs:

Artemether/Lumefantrine

Everolimus

Gadopentetate Dimeglumine

Haloperidol Lactate

Isoniazid/Pyrazinamide/Rifampin

Japanese Encephalitis Virus Vaccine, Inactivated

ACP PIER®: Physicians' Information and Education Resource - What's new in

ACP PIER®: Physicians' Information and Education Resource

©2009 ACP PIER: American College of Physicians Authors/Editors: ACP PIER: American College of Physicians (ACP) © 2008 by the American College of Physicians

NEW MODULE(S):

• None.

UPDATED MODULES:

• Atrioventricular Block
• Community Acquired Pneumonia
• Delirium
• Diabetic Ketoacidosis
• Epilepsy
• Flexible Sigmoidoscopy
• Genetic Counseling
• Hodgkin's Disease
• Hypertension in Pregnancy
• Meningococcal Infection
• Multiple Sclerosis
• Pelvic Inflammatory Disease
• Postpartum Fever
• Rotator Cuff Tendonitis
• Screening for Type 2 Diabetes
• Ulcerative Colitis

ACP PIER, Journal Club & AHFS DI® Essentials™ - What's New in April 2009

ACP PIER, Journal Club & AHFS DI® Essentials™

©2009 by the American College of Physicians

Authors/Editors: American College of Physicians (ACP)

What's New: April 2009 - Volume 150, Number 4

Therapeutics

Review: Transfer for PCI reduces 30-day mortality more than on-site thrombolysis in STEMI

Review: Statins are effective for prevention of cardiovascular events in patients without coronary heart disease

Review: Brand-name drugs are not more effective than generic versions for treating cardiovascular disease Self-monitored, home-based pulmonary rehab was noninferior to outpatient, hospital-based rehab for COPD

Review: Metformin reduces risk for CV mortality compared with other oral diabetes drugs or placebo in type 2 diabetes

Review: Oral drugs for gestational diabetes do not increase adverse maternal and neonatal outcomes more than insulin

Review: Early surgery improves outcomes in patients with primary supratentorial intracerebral hemorrhage

Review: Interferon and nucleoside/tide analogues reduce risk for hepatocellular cancer in patients with chronic hepatitis B Supplementation with vitamin E or vitamin C did not differ from placebo for major cardiovascular events and mortality

Prognosis

Review: Long-term annual conversion rate to dementia was 3.3% in older adults with mild cognitive impairment

Diagnosis

Review: Individual alarm features have moderate-to-high specificity and low sensitivity for diagnosing colorectal cancer

Review: Newer screening tests have varied sensitivity and moderate-to-high specificity for detecting colorectal cancer

APhA DrugInfoLine® - What's New in March 2009

APhA DrugInfoLine®

©2009 American Pharmacists Association (APhA)

Authors/Editors: L. Michael Posey

What's New: March 2009: Vol 10, No 3

Cardiovascular Disorders - Omar Badawi, Section Advisor

• EFFECTIVE DRUG THERAPY FOR IDIOPATHIC RECURRENT VENTRICULAR FIBRILLATION

Oncologic Disorders - Gary C. Yee, Section Advisor

• ROLE OF 5-ALPHA REDUCTASE INHIBITORS FOR PROSTATE CANCER CHEMOPREVENTION

Drug Interactions Corner - Daniel S. Streetman, Section Advisor

• MOST MEDICATION ALERTS OVERRIDDEN

Focus on: Anticoagulation Care - Sarah Ray, Section Advisor

• GENETIC INFORMATION IMPROVES WARFARIN DOSING FOR SOME

Focus on: Diabetes Care - Charles D. Ponte, Section Advisor

• LIRAGLUTIDE: NEXT GLP-1 ANALOG FOR TYPE 2 DIABETES?

Endocrinologic Disorders - Frank Pucino, Section Advisor

• LACK OF COMPLIANCE TO OSTEOPOROSIS MANAGEMENT GUIDELINES

Rheumatologic Disorders - Arthur A. Schuna, Section Advisor

• MALE FERTILITY PROBLEMS NOT OBSERVED DURING INFLIXIMAB TREATMENT

Alternative Medicines Corner - Nicole M. Maisch, Section Advisor

• LOW VITAMIN D LEVELS ASSOCIATED WITH COMMON COLD

Medication Monitor: Updates On Advances In Therapy